Understand the source comparison
Evidence Hierarchy: Preclinical Data vs Clinical Validation
Rapamycin's longevity effects have been replicated in at least four independent mouse strains (C57BL/6, HET3, UM-HET3, genetically heterogeneous mice) across multiple institutions including the National Institute on Aging Interventions Testing Program. The con
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rapamycin's longevity effects have been replicated in at least four independent mouse strains (C57BL/6, HET3, UM-HET3, genetically heterogeneous mice) across multiple institutions including the National Institute on Aging Interventions Testing Program. The consistency is striking: lifespan extension ranges from 9–14% when started mid-life, with dose-dependent effects observed between 4.7 mg/kg and 42 mg/kg feed concentrations.
- Peptide longevity data is far more limited. Epitalon showed a 12.3% increase in mean lifespan in elderly female rats (Anisimov et al., Biogerontology 2003), but this result hasn't been independently replicated outside the Khavinson group. Thymalin studies in rodents report immune restoration and reduced tumor incidence but lack survival curve endpoints. Thymosin alpha-1 has phase II and III human trials for hepatitis B and C. Demonstrating immune modulation. But no completed studies measuring lifespan or age-related disease incidence.
- The reproducibility gap matters enormously. In pharmaceutical development, a finding that can't be replicated across independent labs is treated as preliminary at best. Rapamycin's effects have been confirmed by at least six separate research groups using standardized ITP protocols. Most peptide longevity claims rest on single-lab datasets, often published in lower-impact journals without peer replication.
- What we've learned from years of reviewing this literature: mechanism plausibility doesn't equal efficacy. Telomerase activation sounds promising, and Epitalon demonstrably activates the enzyme in vitro. But that tells us nothing about whether it extends human healthspan. The evidence standard for 'anti-aging' should be survival data in mammals, ideally across multiple genetic backgrounds.